Selumetinib is named as an intervention in 9 current clinical trials in our USA, UK and China registers. None are recruiting at the moment. The most common phase is Phase 1. The sponsor with the most trials is AstraZeneca (7). The most-studied condition is Neurofibromatosis Type 1.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Selumetinib on the HPRA medicines list.
No entry for Selumetinib in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Neurofibromatosis Type 1 | 2 |
| Neurofibromatosis Type 2 | 2 |
| Meningioma | 2 |
| Neurofibromatosis 1 | 1 |
| Plexiform Neurofibroma (PN) | 1 |
| Muscle Invasive Bladder Cancer | 1 |
| Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Advanced Non Small Cell Lung Cancer | 1 |
| NF2 | 1 |
| NF2-related Schwannomatosis | 1 |
| Vestibular Schwannoma | 1 |
| Non-vestibular Schwannoma | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 7 |
| Beijing Tiantan Hospital | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 7 | 0 |
| Clinical trials in UK | 3 | 0 |
| Clinical trials in China | 3 | 0 |
A trial with sites in more than one country appears in each of those registers.
9 current trials in our USA, UK and China registers name Selumetinib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 9 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
AstraZeneca (7) and Beijing Tiantan Hospital (2). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Selumetinib, for example Koselugo 10 mg hard capsules (AstraZeneca AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Selumetinib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Selumetinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Selumetinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Selumetinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.